AR045995A1 - Proceso para la preparacion de derivados de tetrazoles - Google Patents

Proceso para la preparacion de derivados de tetrazoles

Info

Publication number
AR045995A1
AR045995A1 ARP040102491A ARP040102491A AR045995A1 AR 045995 A1 AR045995 A1 AR 045995A1 AR P040102491 A ARP040102491 A AR P040102491A AR P040102491 A ARP040102491 A AR P040102491A AR 045995 A1 AR045995 A1 AR 045995A1
Authority
AR
Argentina
Prior art keywords
residue
formula
preparation
alicyclic
independently
Prior art date
Application number
ARP040102491A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR045995A1 publication Critical patent/AR045995A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/06—Aluminium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/06—Aluminium compounds
    • C07F5/061—Aluminium compounds with C-aluminium linkage
    • C07F5/066—Aluminium compounds with C-aluminium linkage compounds with Al linked to an element other than Al, C, H or halogen (this includes Al-cyanide linkage)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Un proceso para la fabricación de un tetrazol de fórmula 1 o un tautómero o una sal del mismo, en donde R representa un residuo orgánico comprende (i) reaccionar un compuesto de la fórmula R-CN(II a) con una azida de la fórmula (R1) (R2)M-N3 (II b), en donde R tiene el significadp como se define arriba; R1 y R2 independientemente entre sí, representran un residuo orgánico tal como un residuo alifático, un residuo alicíclico, un residuo heteroalicíclico; un residuo alicíclico-alifático; un residuo aromático carbocíclico o heterocíclico; un residuo aralifático o un residuo heteroaralifático, cada residuo, independientemente de otro, substituyéndose o no; y M es boro o aluminio; y (ii) aislar el compuesto resultante de la fórmula (i)
ARP040102491A 2003-07-15 2004-07-15 Proceso para la preparacion de derivados de tetrazoles AR045995A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316546.1A GB0316546D0 (en) 2003-07-15 2003-07-15 Process for the manufacture of organic compounds

Publications (1)

Publication Number Publication Date
AR045995A1 true AR045995A1 (es) 2005-11-23

Family

ID=27763861

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102491A AR045995A1 (es) 2003-07-15 2004-07-15 Proceso para la preparacion de derivados de tetrazoles

Country Status (35)

Country Link
US (3) US7943647B2 (es)
EP (2) EP1646636B1 (es)
JP (2) JP5052132B2 (es)
KR (5) KR20130140915A (es)
CN (1) CN100475823C (es)
AR (1) AR045995A1 (es)
AT (1) ATE450541T1 (es)
AU (1) AU2004263265C1 (es)
BR (1) BRPI0412558A (es)
CA (1) CA2532175A1 (es)
CO (1) CO5670370A2 (es)
CY (1) CY1109809T1 (es)
DE (1) DE602004024402D1 (es)
DK (1) DK1646636T3 (es)
EC (2) ECSP066282A (es)
ES (1) ES2336333T3 (es)
GB (1) GB0316546D0 (es)
HK (1) HK1093509A1 (es)
HR (1) HRP20100088T1 (es)
IL (2) IL172946A (es)
IS (1) IS8303A (es)
MA (1) MA27906A1 (es)
MX (1) MXPA06000561A (es)
MY (1) MY176840A (es)
NO (1) NO20060729L (es)
NZ (1) NZ544644A (es)
PE (2) PE20091786A1 (es)
PL (1) PL1646636T3 (es)
PT (1) PT1646636E (es)
RU (2) RU2006104322A (es)
SI (1) SI1646636T1 (es)
TN (1) TNSN06008A1 (es)
TW (2) TWI340742B (es)
WO (1) WO2005014602A1 (es)
ZA (1) ZA200600312B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
JP4537678B2 (ja) * 2003-09-04 2010-09-01 住友化学株式会社 ２’−（１ｈ−テトラゾール−５−イル）ビフェニル−４−カルボアルデヒド結晶およびその製造方法
EP1661891A1 (en) * 2004-11-30 2006-05-31 KRKA, D.D., Novo Mesto A process for the synthesis of valsartan
GB0514206D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
GB0514686D0 (en) * 2005-07-18 2005-08-24 Novartis Ag Organic compounds
WO2007020654A1 (en) * 2005-08-16 2007-02-22 Suven Life Sciences An improved process for the preparation of losartan
WO2007026375A1 (en) * 2005-08-31 2007-03-08 Suven Life Sciences Process for the preparation of losartan
KR100795589B1 (ko) * 2006-05-29 2008-01-21 주식회사 대희화학 2-부틸-4-클로로-1-[[2'-(1ｈ-테트라졸-5-일)바이페닐-4-일]메틸]이미다졸-5-카르복스알데하이드의 제조방법
CN101200455B (zh) * 2007-09-29 2010-08-18 泰兴市江神化工有限公司 沙坦类治疗高血压药物主环5-(4'-甲酰基联苯-2-基)-1h-四氮唑的制备方法
ATE538105T1 (de) 2007-10-12 2012-01-15 Arqule Inc Substituierte tetrazolverbindungen und ihre verwendung
EP2316821A1 (en) * 2009-10-27 2011-05-04 Novartis AG Process for the manufacture of organic compounds
WO2011061996A1 (ja) * 2009-11-17 2011-05-26 田辺三菱製薬株式会社 ビフェニル誘導体の製法
US10368340B2 (en) * 2010-04-01 2019-07-30 Hon Hai Precision Industry Co., Ltd. Network service exposure method and apparatus utilizing the same
KR101942064B1 (ko) * 2011-04-25 2019-01-24 주식회사 엘지화학 신규한 아연 아지드 착물 및 이를 이용한 테트라졸 유도체의 제조방법
CN102351804B (zh) * 2011-09-30 2013-07-31 浙江新赛科药业有限公司 一种缬沙坦消旋体的回收方法
CN102702117B (zh) * 2012-06-01 2016-04-13 浙江沙星医药化工有限公司 一种制备5-(4’-溴代甲基-2-联苯基)-1-三苯甲基四氮唑的方法
CN103265560B (zh) * 2013-05-17 2016-05-04 中国科学院上海高等研究院 棉酚/棉酮衍生物及其制备方法和抗肿瘤药物中的应用
KR101956281B1 (ko) * 2013-08-13 2019-03-08 삼성전기주식회사 수지 조성물, 이를 이용한 인쇄회로기판 및 그 제조방법
KR102090155B1 (ko) * 2019-11-22 2020-03-17 국방과학연구소 베타인 수용액 내에서 5-치환-1h-테트라졸의 제조방법
US11655220B2 (en) 2020-10-22 2023-05-23 Hetero Labs Limited Process for the preparation of angiotensin II receptor blockers
CN116375687A (zh) * 2021-12-22 2023-07-04 浙江华海药业股份有限公司 一种高纯度的氯沙坦钾及其制备方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2977372A (en) * 1958-04-09 1961-03-28 William G Finnegan Process for preparing substituted tetrazoles
US3394142A (en) * 1966-01-19 1968-07-23 Minnesota Mining & Mfg Substituted tetrazoles and process therefor
CH499526A (de) 1968-06-06 1970-11-30 Ciba Geigy Ag Verfahren zur Herstellung von neuen Tetrazolderivaten
SU497775A3 (ru) 1970-01-16 1975-12-30 Циба-Гейги Аг (Фирма) Способ получени производных тетразола
DE2650231A1 (de) * 1976-11-02 1978-05-11 Hoechst Ag Neue imidazolverbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4097479A (en) * 1977-03-11 1978-06-27 Miles Laboratories, Inc. Synthesis of 5-substituted tetrazoles
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
US4288352A (en) 1979-03-26 1981-09-08 Exxon Research & Engineering Co. Electrically conductive polymeric compositions
FI73423C (fi) * 1980-02-29 1987-10-09 Otsuka Pharma Co Ltd Foerfarande foer framstaellning av farmakologiskt verksamma tetrazolderivat.
JPS56158781A (en) 1980-05-10 1981-12-07 Kaken Pharmaceut Co Ltd Tetrazolecoumarin derivative, its preparation and antiallergic agent containing the same as active constitutent
US4338452A (en) * 1980-09-17 1982-07-06 Eli Lilly And Company 1-and 2-(1-Alkyl-1H-tetrazol-5-yl-methyl)-1H-tetrazol-5-thiols and 1-cyanomethyl tetrazole-5-thiol
US4735948A (en) 1983-03-25 1988-04-05 Merrell Dow Pharmaceuticals Inc. (1H-tetrazol-5-yl)-2(1H)-quinolinones and-naphthyridones and antiallergic use thereof
JPS6073028A (ja) 1983-09-29 1985-04-25 Japan Electronic Control Syst Co Ltd 電子制御燃料噴射式内燃機関の始動時の噴射量の学習制御装置
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
GB8708459D0 (en) 1987-04-09 1987-05-13 Avdel Ltd Fastener installation apparatus
US4874867A (en) * 1987-05-22 1989-10-17 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4870186A (en) * 1987-05-22 1989-09-26 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4820843A (en) 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4831192A (en) * 1987-12-31 1989-05-16 Boc, Inc. Methods of preparing 4-heteropentacyclic-4-(N-phenyl)amido) piperidine derivatives and intermediate compounds
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
US5128069A (en) * 1989-03-22 1992-07-07 Nippon Zoki Pharmaceutical Co., Ltd. Luciferin derivatives
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
JPH04297466A (ja) 1990-06-22 1992-10-21 Nippon Shinyaku Co Ltd テトラゾール誘導体及び医薬
US5284954A (en) 1990-09-10 1994-02-08 Abbott Laboratories Process for the preparation of tetrazoles
AU9137791A (en) 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
US5591762A (en) * 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5602127A (en) * 1991-02-06 1997-02-11 Karl Thomae Gmbh (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
CA2229000C (en) 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
JP2524842Y2 (ja) 1991-02-28 1997-02-05 三菱重工業株式会社 原紙供給装置
US5447949A (en) * 1991-05-15 1995-09-05 Smithkline Beecham Corporation N-(heteroaryl) imidazolyl-alkenoic acids having angiotension II receptor antagonist activity
AU2494792A (en) 1991-08-19 1993-03-16 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
ATE144501T1 (de) 1991-08-22 1996-11-15 Warner Lambert Co Tetrazolamide als acat inhibitoren
EP0550313A1 (fr) * 1991-12-30 1993-07-07 Synthelabo Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
WO1993014086A1 (en) 1992-01-17 1993-07-22 Syntex (U.S.A.) Inc. Substituted 1-isoquinolone derivatives as angiotensin ii antagonists
DE4203872A1 (de) * 1992-02-11 1993-08-12 Thomae Gmbh Dr K Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4206045A1 (de) 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl substituierte pyridone
US5484955A (en) 1992-07-06 1996-01-16 Takeda Chemical Industries, Ltd. Tri-higher alkyl tin azide and its use
JP2990566B2 (ja) * 1992-07-06 1999-12-13 武田薬品工業株式会社 トリ高級アルキルスズアジドおよびその用途
JPH06107658A (ja) 1992-09-28 1994-04-19 Kanebo Ltd 新規なピラジン誘導体
US5256658A (en) * 1993-01-15 1993-10-26 Ortho Pharmaceutical Corporation Angiotensin II inhibitors
US5502191A (en) * 1993-07-01 1996-03-26 American Cyanamid Company Method of synthesizing sterically hindered 5-substituted-1H-tetrazoles from nitriles using a lewis acid and an azide
EP0736021A4 (en) * 1993-12-23 1997-04-02 Merck & Co Inc LOSARTANE POLYMORPHS AND PROCESS FOR THE PREPARATION OF FORM II OF LOSARTANE
AU686761B2 (en) 1994-03-25 1998-02-12 Merrell Pharmaceuticals Inc. Process for preparing (1H-tetrazol-5-yl)tetrazolo (1,5-a) quinolines and naphthyridines
ATE169298T1 (de) 1994-03-28 1998-08-15 Pfizer Benzisothiazol-derivate als inhibitoren der 5- lipoxygenase biosynthese
US5541209A (en) 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
JPH08325248A (ja) 1995-05-26 1996-12-10 Chugoku Kayaku Kk テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法
JP3671266B2 (ja) 1996-03-21 2005-07-13 東洋化成工業株式会社 ５−置換テトラゾール類の製造方法
JPH10218868A (ja) 1997-02-12 1998-08-18 Toyo Kasei Kogyo Co Ltd ５ーメチルテトラゾールの製造方法
JP4450881B2 (ja) 1998-12-28 2010-04-14 株式会社日本ファインケム ５，５’−ビ−１ｈ−テトラゾール塩の製造方法
JP2000281662A (ja) 1999-03-31 2000-10-10 Masuda Kagaku Kogyo Kk テトラゾール類の製造方法
DE19935219A1 (de) * 1999-07-27 2001-02-01 Boehringer Ingelheim Pharma Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
DE60025831T2 (de) * 1999-09-27 2006-08-10 Dow Global Technologies, Inc., Midland Expandierte anionen enthaltende geträgertes katalysatorsystem
US20040072886A1 (en) * 2002-04-15 2004-04-15 Dr. Reddy's Laboratories Limited Novel crystalline forms of (S)-N- (1-Carboxy-2-methyl-prop-1-yl) -N-pentanoyl-N- [2' -(1H-tetrazol-5-yl)- biphenyl-4-yl methyl] amine (Valsartan)
GB0222056D0 (en) 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
US6934312B2 (en) * 2002-09-30 2005-08-23 Agilent Technologies, Inc. System and method for fabricating efficient semiconductor lasers via use of precursors having a direct bond between a group III atom and a nitrogen atom
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
CA2534892A1 (en) * 2003-08-08 2005-02-17 Dipharma S.P.A. A process for the preparation of phenyltetrazole derivatives
JP2007529629A (ja) 2004-03-17 2007-10-25 ケネコツト・ユタ・コツパー・コーポレーシヨン 電解セル電流のモニタリング

Also Published As

Publication number Publication date
KR20120018826A (ko) 2012-03-05
JP2011184451A (ja) 2011-09-22
EP2116548A1 (en) 2009-11-11
GB0316546D0 (en) 2003-08-20
TW201038540A (en) 2010-11-01
IS8303A (is) 2006-02-14
EP1646636B1 (en) 2009-12-02
KR20130127011A (ko) 2013-11-21
AU2004263265A1 (en) 2005-02-17
RU2006104322A (ru) 2007-09-20
US20110184187A1 (en) 2011-07-28
IL172946A0 (en) 2006-06-11
TWI372754B (en) 2012-09-21
HK1093509A1 (en) 2007-03-02
ES2336333T3 (es) 2010-04-12
KR20060038994A (ko) 2006-05-04
DK1646636T3 (da) 2010-04-06
ECSP11006282A (es) 2011-08-31
PE20050710A1 (es) 2005-09-28
MY176840A (en) 2020-08-24
AU2004263265C1 (en) 2008-09-25
JP5052132B2 (ja) 2012-10-17
US20120330026A1 (en) 2012-12-27
IL216449A0 (en) 2011-12-29
CY1109809T1 (el) 2014-09-10
TW200510347A (en) 2005-03-16
CN1852908A (zh) 2006-10-25
CO5670370A2 (es) 2006-08-31
NZ544644A (en) 2008-07-31
CN100475823C (zh) 2009-04-08
HRP20100088T1 (hr) 2010-06-30
KR101336435B1 (ko) 2013-12-04
ZA200600312B (en) 2007-02-28
WO2005014602A1 (en) 2005-02-17
JP2009513555A (ja) 2009-04-02
EP1646636A1 (en) 2006-04-19
RU2012149012A (ru) 2014-05-27
PT1646636E (pt) 2010-01-29
IL172946A (en) 2012-01-31
DE602004024402D1 (de) 2010-01-14
US20070043098A1 (en) 2007-02-22
MA27906A1 (fr) 2006-05-02
TWI340742B (en) 2011-04-21
CA2532175A1 (en) 2005-02-17
PE20091786A1 (es) 2009-12-14
US7943647B2 (en) 2011-05-17
NO20060729L (no) 2006-04-04
ATE450541T1 (de) 2009-12-15
KR20130140915A (ko) 2013-12-24
ECSP066282A (es) 2006-07-28
MXPA06000561A (es) 2006-03-30
KR20110082096A (ko) 2011-07-15
SI1646636T1 (sl) 2010-03-31
PL1646636T3 (pl) 2010-05-31
AU2004263265B2 (en) 2007-09-06
US8569528B2 (en) 2013-10-29
BRPI0412558A (pt) 2006-09-19
TNSN06008A1 (en) 2007-10-03

Similar Documents

Publication Publication Date Title
AR045995A1 (es) Proceso para la preparacion de derivados de tetrazoles
AR046083A1 (es) Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
BRPI0412352A (pt) processo para a preparação de derivados de tetrazol de azidas de organo boro e organo alumìnio
TN2010000053A1 (fr) Derives de bi cyclolactames substitues
AR054088A1 (es) Triazoles como inhibidores de proteinquinasas. composiciones farmaceuticas
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
AR054809A1 (es) Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20090840A1 (es) Moleculas pequenas que contienen boro
MY144903A (en) Pyrrolopyridine derivatives and their use as crth2 antagonists
NO20064669L (no) Dipeptidylpeptidaseinhibitorer
PE20121282A1 (es) Antagonistas de espiro-oxindol de mdm2
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
US3835142A (en) 1-(2-imidazolin-2-yl)-2-(1,2,3,4-tetrahydro-2-isoquinolyl)-2-imidazolines
AR062258A1 (es) Compuestos heterociclicos condensados de tieno-pirrol, composiciones farmaceuticas que los contienen y usos para el tratamiento de infecciones por hcv
GB0412769D0 (en) Organic compounds
PE20070122A1 (es) Proceso para preparar derivados de piperazina azindoloxoacetica sustituida con triazol y nuevas formas de sal producidas de los mismos
ECSP066983A (es) Un método fácil para sintetizar compuestos de bacatina iii
AR064626A1 (es) Sintesis de compuestos de pirrolidina
PE20120026A1 (es) 2-metil-1-(fenilsulfonil)-4-piperazin-1-il-1h-benzimidazol como ligando de 5-hidroxitriptamina-6 (5-ht6)
AR039111A1 (es) Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal